ProSomnus Sleep Technologies, featuring the MicrO2 obstructive sleep apnea and snore device, has separated from MicroDental Laboratories. This strategic move enables ProSomnus to operate as a standalone business and concentrate resources on partnering with dentists to treat the rapidly growing number of patients with obstructive sleep apnea (OSA).
“ProSomnus invents and manufactures devices that enable dentists to treat more patients who are suffering from OSA. Tens of millions of adults have undiagnosed OSA, millions of adults have abandoned CPAP, and dentists can help,” says Len Liptak, CEO of ProSomnus Sleep Technologies, in a release. “Separating from MicroDental Laboratories enables ProSomnus to accelerate development of the key products, processes, and programs that are integral to this plan.”
ProSomnus Sleep Technologies is a member of private equity firm HealthpointCapital’s portfolio of investments.
“A few years ago, HealthpointCapital identified the obstructive sleep apnea market as an attractive opportunity,” says Laing Rikkers, managing director at HealthpointCapital. “HealthpointCapital invests in innovative device companies that are addressing underserved healthcare issues, and ProSomnus fits this profile. We look forward to partnering with the leadership team at ProSomnus to expand the oral appliance therapy segment of the sleep apnea market.”